TRT After Anabolic Steroid Use: Restoring Testosterone When the HPG Axis Has Been Suppressed

Why Anabolic Steroid Use Causes Hypogonadism

Exogenous androgens shut down the HPG axis within days. The hypothalamus reads high circulating androgen levels and cuts gonadotropin-releasing hormone (GnRH) pulse frequency. The pituitary responds by drastically reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) output. Without LH signal, the Leydig cells in the testes stop producing endogenous testosterone. Without FSH, Sertoli cells stop supporting sperm maturation. Both functions can remain suppressed long after the last AAS dose.

A 2019 cross-sectional study published in the Journal of Clinical Endocrinology and Metabolism (N=132 former AAS users) found that 43% of men who had stopped AAS use for a median of 32 months still had serum testosterone levels below 300 ng/dL. [1] That figure compares with roughly 2.1% hypogonadism prevalence in age-matched non-users. The probability of persistent suppression rises steeply with both cumulative dose and cycle duration. Men who ran cycles longer than 16 weeks or stacked three or more compounds showed the greatest degree of lasting Leydig cell dysfunction.

The deficit is not always irreversible. Leydig cell mass can recover, but recovery is uneven. Some men normalize LH and testosterone within 3 to 4 months of stopping. Others, especially those who used for more than 3 to 5 years, may have enough Leydig cell atrophy that endogenous production never returns to a eugonadal range. [2] Distinguishing these two groups before prescribing TRT is the clinical challenge every practitioner faces.

Primary vs. Secondary Hypogonadism: Why the Distinction Matters for Former Steroid Users

The terms get used interchangeably but they describe completely different physiological failures. Primary hypogonadism originates in the testes. The pituitary sends adequate LH signal but the testes cannot respond. FSH and LH are elevated on labs. Secondary hypogonadism originates above the gonads, in the hypothalamus or pituitary. LH and FSH are low or inappropriately normal despite low testosterone.

AAS-induced hypogonadism is almost always secondary at first. The HPG axis was simply switched off by exogenous androgens. Over time, however, prolonged suppression can cause testicular atrophy severe enough to add a primary component, making recovery less predictable. [3]

This distinction shapes treatment decisions directly. A man with clearly secondary hypogonadism and an intact HPG axis who still wants biological children should try axis-stimulation strategies, such as hCG (human chorionic gonadotropin) or clomiphene citrate, before committing to TRT. A man with mixed primary-secondary failure who has completed his family may move directly to testosterone therapy. The Endocrine Society's 2018 Clinical Practice Guideline states: "We suggest against making a diagnosis of androgen deficiency in men with a transient condition that might suppress serum testosterone levels." [4] That directive applies precisely to the post-cycle window.

The Post-Cycle Recovery Assessment: What Labs to Order and When

Do not prescribe TRT the week after someone stops a cycle. The assessment must be done after a waiting period long enough to distinguish transient suppression from durable hypogonadism.

The minimum waiting period before diagnostic labs is 3 months after the last AAS dose for short esters (testosterone propionate, trenbolone acetate) and 4 to 6 months after cessation for long esters or oral compounds that accumulate hepatically (nandrolone decanoate, oxandrolone). Some very long nandrolone ester metabolites remain detectable and biologically active for up to 6 months after the last injection. [5]

Once the waiting period passes, the diagnostic workup should include:

• Total testosterone (two morning fasting samples drawn between 7 a.m. and 10 a.m., at least one week apart)
• Free testosterone (calculated or equilibrium dialysis)
• LH and FSH (to classify primary vs. secondary)
• Prolactin (to exclude a pituitary adenoma driving suppression)
• SHBG (sex hormone-binding globulin, which affects free T interpretation)
• Estradiol (sensitive LC-MS/MS assay, not immunoassay)
• CBC, comprehensive metabolic panel, lipid panel (safety baseline)
• Testicular ultrasound if physical exam reveals marked atrophy

The Endocrine Society defines hypogonadism by total testosterone consistently below 300 ng/dL in conjunction with clinical symptoms. [4] Symptoms alone are insufficient; labs alone are insufficient. Both must be present.

Axis Stimulation Before TRT: hCG and Clomiphene Options

Men who are hypogonadal 3 to 6 months after stopping AAS but who want to father children should not go directly onto testosterone. TRT suppresses spermatogenesis as effectively as the original AAS did. The preferred options for this group are hCG monotherapy, clomiphene citrate, or a combination.

hCG mimics LH and directly stimulates testicular Leydig cells. Typical dosing is 1,500 to 2 to 000 IU subcutaneously every other day for 8 to 12 weeks. A 2013 trial in the European Journal of Endocrinology (N=29 hypogonadal men post-AAS) showed hCG restored testosterone above 400 ng/dL in 21 of 29 subjects within 8 weeks. [6] Men who respond demonstrate that Leydig cell mass is sufficient; those who do not respond are candidates for TRT.

Clomiphene citrate (25 to 50 mg daily or every other day) blocks estrogen receptors in the hypothalamus, increasing GnRH and thus LH pulse amplitude. It works when the pituitary and testes are functional but the hypothalamus is suppressed. It does not work when Leydig cell atrophy is primary. A 6-month clomiphene trial is reasonable before concluding TRT is necessary. [7]

If testosterone remains below 300 ng/dL and symptoms persist after two documented axis-stimulation attempts totaling at least 3 to 4 months, moving to TRT is appropriate.

Starting TRT After Anabolic Steroid Use: Formulation, Dosing, and Protocol

Once TRT candidacy is confirmed, the approach for former AAS users does not differ fundamentally from TRT in age-related hypogonadism, but a few practical points apply.

Formulation options include:

• Testosterone cypionate or enanthate (IM or subcutaneous): 100 to 200 mg every 7 to 14 days, or 50 to 70 mg weekly for steadier serum levels and less erythrocytosis risk
• Testosterone undecanoate injection (Aveed, Jatenzo): longer dosing intervals (every 10 weeks after loading), preferred for patients who find frequent injections burdensome
• Transdermal gels (AndroGel 1.62%, Testim, Vogelxo): 20.25 to 81 mg daily; useful for men sensitive to injection-related hematocrit spikes
• Subcutaneous pellets (Testopel): 150 to 450 mg implanted every 3 to 6 months

Former steroid users are often experienced with injection technique. The greater clinical risk is that they self-dose toward supraphysiologic levels based on prior AAS experience. TRT targets a trough total testosterone of 400 to 700 ng/dL, not the 1,000 to 2 to 500 ng/dL levels common in AAS cycles. Over-dosing increases hematocrit, erythropoiesis, and cardiovascular risk. The FDA-approved labeling for testosterone cypionate specifies a target range of 400 to 700 ng/dL at trough; exceeding 1 to 000 ng/dL at trough warrants dose reduction. [8]

Starting with a lower dose and titrating upward based on labs at 6 to 8 weeks is safer than starting high and adjusting down. A reasonable opening protocol is 80 to 100 mg testosterone cypionate weekly, subcutaneous injection, with a trough drawn before the next dose at week 6.

HealthRX Post-AAS TRT Decision Framework

1. Wait at least 3 to 6 months after last AAS dose before drawing diagnostic labs
2. Confirm hypogonadism on two morning total T samples (<300 ng/dL) plus clinical symptoms
3. Measure LH, FSH, prolactin to classify etiology
4. If fertility desired, attempt hCG and/or clomiphene for 3 to 4 months before TRT
5. If no fertility goal or axis-stimulation fails, initiate TRT at physiologic replacement dose
6. Add anastrozole (0.25 to 0.5 mg twice weekly) only if estradiol exceeds 50 pg/mL with symptoms; do not use prophylactically
7. Monitor CBC, total T (trough), estradiol, PSA at 6 weeks, 3 months, 6 months, then every 6 months

TRT and Erectile Dysfunction in Former Steroid Users

Low testosterone is one cause of erectile dysfunction, but not the only one. Erections require adequate nitric-oxide-mediated vascular relaxation, intact neurological signaling, and sufficient psychological drive. All three pathways can be impaired independently of testosterone levels.

Among former AAS users, vascular dysfunction may compound hypogonadal ED. Supraphysiologic AAS exposure is associated with reduced left ventricular ejection fraction, endothelial dysfunction, and accelerated atherosclerosis. A 2017 study in Circulation (N=140, including 86 current or former AAS users) found that former AAS users had significantly lower coronary flow reserve than non-users (2.9 vs. 3.9, P<0.001), indicating subclinical coronary microvascular dysfunction that persists years after stopping. [9] Impaired penile arterial flow from this mechanism will not resolve with testosterone alone.

The clinical approach should therefore be layered. Restore testosterone to the physiologic range first, because hypogonadism independently reduces libido and contributes to ED through reduced cavernous smooth muscle responsiveness. If ED persists after 3 to 6 months of stable TRT, a PDE5 inhibitor (sildenafil 25 to 100 mg PRN, or tadalafil 5 mg daily) is the appropriate next step. The combination of TRT plus a PDE5 inhibitor outperforms either agent alone in men with both hypogonadism and ED. A 2014 meta-analysis of 7 randomized controlled trials (N=868) in the Journal of Sexual Medicine confirmed that testosterone therapy significantly improved erectile function scores in hypogonadal men, with additional gains when a PDE5 inhibitor was co-prescribed. [10]

TRT and Low Libido After Steroid Use

Libido is one of the earliest casualties of hypogonadism and one of the first symptoms to recover on TRT. The mechanism is partly central: testosterone and its aromatized product estradiol both act on hypothalamic androgen and estrogen receptors to drive sexual motivation. Low T reduces dopaminergic tone in the mesolimbic system, which is a major driver of desire and reward-seeking behavior.

Former AAS users sometimes report complete absence of sexual interest during the trough of post-cycle hypogonadism. They describe the phase as feeling "flatlined," with no arousal response to visual stimuli and indifference to partners they were previously attracted to. This is a recognized clinical presentation, not a psychological quirk. It reflects measurable reductions in serum testosterone, free testosterone, and often estradiol simultaneously.

Libido typically begins recovering 3 to 6 weeks after stable TRT serum levels are achieved. The Endocrine Society notes that "sexual function, including libido and erectile function, improves within 3 weeks to 3 months in most hypogonadal men started on testosterone therapy." [4] Full normalization may take 3 to 6 months as hypothalamic sensitivity recalibrates. If libido remains low despite testosterone in the 500 to 700 ng/dL range, a secondary cause should be evaluated: depression, elevated prolactin, low estradiol from over-aromatase-inhibition, or sleep apnea each independently suppress desire.

Monitoring, Safety, and Long-Term Considerations

TRT in former AAS users carries the same risks as TRT in any man, with one additional concern: hematocrit elevation tends to be more pronounced in this population, possibly from prior erythropoietic priming by supraphysiologic androgens.

The FDA requires monitoring of hematocrit at baseline and periodically thereafter. If hematocrit exceeds 54%, the dose should be reduced or therapy paused until values return to normal. [8] Polycythemia from TRT increases blood viscosity and carries a thrombotic risk that must be taken seriously.

Other monitoring priorities:

• PSA: Measure at baseline, 3 months, 6 months, then annually. Testosterone does not cause prostate cancer, but may stimulate occult disease. A rise of >1.4 ng/mL above baseline within 12 months warrants urology referral per Endocrine Society guidance. [4]
• Cardiovascular: Former AAS users should have an echocardiogram and lipid panel before starting TRT. Baseline left ventricular hypertrophy from prior cycles is not rare and may worsen with supraphysiologic dosing.
• Estradiol: Aim for estradiol between 20 and 40 pg/mL. Values above 50 pg/mL with gynecomastia or water retention warrant consideration of dose reduction before adding an aromatase inhibitor.
• Bone density: Secondary hypogonadism of more than 12 months duration warrants a DEXA scan to assess bone mineral density. Testosterone therapy consistently improves BMD in hypogonadal men. [11]

Labs should be drawn at weeks 6 and 12 after initiation, then every 3 months for the first year, then every 6 months once the patient is stable and compliance is established.

Andropause vs. AAS-Induced Hypogonadism: Recognizing the Difference

Late-onset hypogonadism (often called andropause) is age-related testosterone decline, typically starting after age 40. Serum testosterone falls roughly 1 to 2% per year after age 30. [12] AAS-induced hypogonadism can look identical on a lab sheet but is mechanistically distinct and occurs in men who may be in their 20s or early 30s.

The practical difference lies in the LH/FSH pattern and the age of onset. An otherwise healthy 28-year-old with total T of 210 ng/dL and LH of 0.8 mIU/mL is not experiencing age-related decline. He has iatrogenic HPG suppression. The workup and management differ accordingly.

Clinicians who see former AAS users and default to an andropause framing miss the suppressed gonadotropin pattern that points to the real diagnosis. A thorough history of prior AAS use, including compounds, doses, cycle lengths, and any post-cycle therapy (PCT) attempts, is the single most important data point in the initial evaluation. Men do not always volunteer this information; direct, non-judgmental questioning is necessary.

What to Expect on TRT: A Realistic Timeline

Patients coming off years of supraphysiologic AAS cycles sometimes expect TRT to replicate those effects. It will not. TRT replaces a physiologic need; it is not an anabolic cycle. Setting expectations correctly at the start reduces non-compliance and dose escalation.

The typical clinical progression looks like this:

Weeks 1 to 4: Sleep quality and mood often improve first. Some men notice morning erections returning. Energy levels begin to lift.

Weeks 4 to 8: Libido becomes more consistent. Erectile quality improves if low T was the primary driver. Mild improvements in motivation and cognitive clarity.

Months 3 to 6: Body composition changes become measurable. Lean mass increases modestly (typically 2 to 4 kg over 6 months in a 70 kg man on physiologic TRT, versus the 6 to 12 kg gains men recall from AAS cycles). Fat mass declines, particularly visceral fat.

Months 6 to 12: Bone density starts improving. Most patients report stable, consistent symptom relief. The goal is a sustainable quality-of-life improvement, not peak performance enhancement.

Former AAS users who understand this timeline are far less likely to abandon TRT prematurely or self-supplement with black-market androgens.